POINT Biopharma Global (NASDAQ:PNT) is accelerating the development of precision medicines for the treatment of cancer, with a late- and early-stage pipeline of radiopharmaceuticals, a technology platform for pipeline...
Brookline Capital Markets initiated coverage of POINT Biopharma (NASDAQ:PNT) with a “buy” rating and $23 price target. The stock closed at $8.07 on Nov. 30. POINT is a late-stage clinical oncology company focused on...
POINT Biopharma Global (NASDAQ:PNT) entered into a technology license agreement with the Belgian Nuclear Research Center (SCK CEN) for Lu-177 purification technology to accelerate POINT’s in-house no-carrier-added...
POINT Biopharma Global (NASDAQ:PNT) and IONETIX, a leading cyclotron technology and isotope manufacturing company, entered into a long-term supply agreement for actinium-225 (Ac-225) to support POINT’s validation, drug...
Radiopharmaceuticals developer, POINT Biopharma Global (NASDAQ:PNT), and Kinectrics entered into a long-term supply agreement for Ytterbium-176 (Yb-176) to support POINT’s in-house no-carrier added Lutetium-177 (n.c.a...
Daniel Pearlstein was named associate director, corporate strategy, of POINT Biopharma (NASDAQ:PNT), which debuted on the Nasdaq Capital Market on July 1, 2021. Mr. Pearlstein was formerly EVP for...